Brief: Sequana Medical: Positive Data From MOJAVE Study Of DSR 2.0 For Treatment Of Heart Failure

Sequana Medical NV

29/11/2023 06:04

Nov 29 (Reuters) - Sequana Medical NV  SEQUA.BR :
    * SEQUANA MEDICAL ANNOUNCES POSITIVE DATA FROM
NON-RANDOMIZED
COHORT IN US PHASE 1/2A MOJAVE STUDY OF DSR® 2.0 FOR TREATMENT
OF HEART FAILURE
    * DSMBI REVIEW PLANNED FOR EARLY Q1 2024 TO APPROVE START OF
RANDOMIZED CONTROLLED COHORT OF UP TO 30 US PATIENTS
    * DATA FROM ALL THREE PATIENTS IN NON-RANDOMIZED COHORT
TREATED
WITH DSR 2.0 INDICATE SAFE AND EFFECTIVE MAINTENANCE OF
EUVOLEMIA WITHOUT NEED FOR LOOP DIURETICS
    * DATA INDICATE DRAMATIC IMPROVEMENT IN DIURETIC RESPONSE
AND LOOP
DIURETIC REQUIREMENTS UP TO 11 WEEKS POST DSR TREATMENT
    * DATA INDICATE CONSIDERABLE BENEFIT IN CARDIORENAL STATUS

Source text for Eikon:  ID:nGNXb2RcpN 
Further company coverage:  SEQUA.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))